CC-214-2

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameCC-214-2
Drug Alias NameCC-214-2CC214-2
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnti-EGFRvIII
TargetsEpidermal growth factor receptor variant III
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A